✨ Free AI Report
Keenova Therapeutics (formerly Mallinckrodt Pharmaceuticals): Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Keenova Therapeutics (formerly Mallinckrodt Pharmaceuticals)
Research Preview

Keenova Therapeutics (formerly Mallinckrodt Pharmaceuticals): Business Overview, Financials & Competitive Analysis

Mallinckrodt completed the spin-off of Par Health and rebranded as Keenova Therapeutics, focusing on developing and commercializing branded therapeutics for patients with rare or unaddressed conditions. The company re...

Analyst-debate audio for Keenova Therapeutics (formerly Mallinckrodt Pharmaceuticals)

AskCyborg analysts argue the bull and bear cases for Keenova Therapeutics (formerly Mallinckrodt Pharmaceuticals) across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Keenova Therapeutics (formerly Mallinckrodt Pharmaceuticals) OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
5/ 10Mixed

Cyborg Score thesis

Keenova represents a turnaround story with established products in growing rare disease markets, but faces execution risk and...

Read the full analyst-debate transcript →
Industry Specialty Pharmaceuticals - Rare & Orphan Diseases
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: June 29, 2026
AI-Verified Research
30+ Page Report

Get the Latest Keenova Therapeutics (formerly Mallinckrodt Pharmaceuticals) Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Keenova Therapeutics (formerly Mallinckrodt Pharmaceuticals) Overview

Pro stress-test →

Mallinckrodt completed the spin-off of Par Health and rebranded as Keenova Therapeutics, focusing on developing and commercializing branded therapeutics for patients with rare or unaddressed conditions. The company reported pro-forma 2024 revenue of $1.7B with 1,600 employees and is headquartered in Dublin.

Strategic Profile

Pro stress-test →

Key products include Acthar Gel for inflammatory/autoimmune conditions and XIAFLEX for Dupuytren's contracture and Peyronie's disease. Keenova intends to pursue a NYSE listing in 2026.

Competitive Landscape

Pro stress-test →

Keenova competes in autoimmune and rare diseases across neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology and oncology. Key competitors include other rare disease specialists like Alexion (AstraZeneca subsidiary), Horizon Therapeutics, and Ultragenyx, as well as larger pharma companies with rare disease portfolios.

Industry Context

Keenova Therapeutics (formerly Mallinckrodt Pharmaceuticals) operates in Specialty Pharmaceuticals - Rare & Orphan Diseases.

Key facts

Founded: 1867 · Headquarters: Dublin, Ireland · Employees: 1,600 · Revenue: $1.7B · Market cap: $4.5M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Keenova Therapeutics (formerly Mallinckrodt Pharmaceuticals).

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Keenova Therapeutics (formerly Mallinckrodt Pharmaceuticals) has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Soliris/UltomirisComplement inhibitors for autoimmune conditions→TepezzaIGF-1 receptor inhibitor for thyroid eye disease→Various Orphan DrugsRare metabolic and genetic disease treatments→

Compare Keenova Therapeutics (formerly Mallinckrodt Pharmaceuticals) with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Keenova Therapeutics (formerly Mallinckrodt Pharmaceuticals) operates in Specialty Pharmaceuticals - Rare & Orphan Diseases. See how the rest of the sector scores on the Cyborg framework.

Browse Specialty Pharmaceuticals - Rare & Orphan Diseases research →
NEW · MCP server

Ask your AI assistant about Keenova Therapeutics (formerly Mallinckrodt Pharmaceuticals)

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Keenova Therapeutics (formerly Mallinckrodt Pharmaceuticals) and its top competitor on Cyborg Score”
“What did Keenova Therapeutics (formerly Mallinckrodt Pharmaceuticals) do this quarter?”
“Is Keenova Therapeutics (formerly Mallinckrodt Pharmaceuticals) a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Keenova Therapeutics (formerly Mallinckrodt Pharmaceuticals) do?+
Mallinckrodt completed the spin-off of Par Health and rebranded as Keenova Therapeutics, focusing on developing and commercializing branded therapeutics for patients with rare or unaddressed conditions. The company re...
What is Keenova Therapeutics (formerly Mallinckrodt Pharmaceuticals)'s Cyborg Score?+
Keenova Therapeutics (formerly Mallinckrodt Pharmaceuticals) has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Keenova Therapeutics (formerly Mallinckrodt Pharmaceuticals)'s main competitors?+
Named competitors include Soliris/Ultomiris, Tepezza, Various Orphan Drugs. The full competitive landscape is in the AskCyborg report.
How can I get the full Keenova Therapeutics (formerly Mallinckrodt Pharmaceuticals) research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Keenova Therapeutics (formerly Mallinckrodt Pharmaceuticals) research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Keenova Therapeutics (formerly Mallinckrodt Pharmaceuticals) over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

Other strong performers across the analyst-debate framework. Click any to see their research report.

9Sezzle Inc.9Carpenter Technology Corporation9Credo Technology Group Holding Ltd9TE Connectivity plc9Rheinmetall AG9Northrop Grumman Corporation9Interactive Brokers Group, Inc.9Berkshire Hathaway Inc.9Mastercard Incorporated8Vera Therapeutics, Inc.8Quoin Pharmaceuticals, Ltd.8Prenetics Global Limited8Strattec Security Corporation8Lesaka Technologies Inc.8Abu Dhabi Ship Building PJSC8Judges Scientific plc8Weathernews Inc.8Orrstown Financial Services, Inc.